Naiyer A. Rizvi, MD, Price Family ​Professor of ​Medicine, director, Thoracic Oncology, co-director, Cancer Immunotherapy, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, research director, Price Family Comprehensive Center for Chest Care, NewYork-Presbyterian Hospital, discusses the utility of fam-trastuzumab deruxtecan-nxki (Enhertu) in non–small cell lung cancer (NSCLC).


Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi. 

, trastuzumab deruxtecan induced a confirmed objective response rate of 61.9%, includ​ing a 2.4% complete response rate, a 59.5% partial response rate, and a 28.6% stable disease rate.

Future research should explore this agent in the first-line setting as a single agent and a combination therapy, Rizvi concludes.

Videos

Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki  in non–small cell lung cancer. 

Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC 

Nathan A. Pennell, MD, PhD, an associate professor in the Department of Medicine and director of the Lung Cancer Medical Oncology Program at the Taussig Cancer Institute of Cleveland Clinic, discusses remaining challenges in non–small cell lung cancer (NSCLC).

Tremendous progress has been made in the NSCLC space over the past decade, says Pennell. There have been several new discoveries in terms of targeted therapies for patients with 

Although immunotherapy has been practice changing, it is effective in a minority of patients with metastatic disease. Therefore, research is needed to enhance the efficacy ​of this modality.

To that end, research is focused on ​developing novel immunotherapy combinations​, as well as personalizing treatment through the use of T cells, ​says Pennell.

In addition to evaluating novel agents, the field should focus on ​improving access to currently available therapies as recent studies have shown that less than half of patients with targetable genetic alterations are identified and treated appropriately, Pennell concludes. 

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Updates and New Targets in NSCLC: An OncLive® Scientific Interchange and Workshop | Supplements and Featured Publications

Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC

Dr. Pennell on Remaining Challenges in NSCLC